| Line |
Label |
Object Class |
Period Type |
Balance |
Report ElementName |
| 1 |
001 - Document - Document and Entity Information |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DocumentAndEntityInformation |
| 2 |
Implied Table |
Table |
* |
* |
implied:Table |
| 3 |
Document and Entity Information [Abstract] |
Abstract |
|
|
tril:DocumentAndEntityInformationAbstract |
| 4 |
Entity Registrant Name |
Concept (Text/String) |
For Period |
|
dei:EntityRegistrantName |
| 5 |
Entity Central Index Key |
Concept (CIK Number) |
For Period |
|
dei:EntityCentralIndexKey |
| 6 |
Trading Symbol |
Concept (Text/String) |
For Period |
|
dei:TradingSymbol |
| 7 |
Document Type |
Concept (Submission Type) |
For Period |
|
dei:DocumentType |
| 8 |
Amendment Flag |
Concept (Yes/No) |
For Period |
|
dei:AmendmentFlag |
| 9 |
Document Period End Date |
Concept (Date) |
For Period |
|
dei:DocumentPeriodEndDate |
| 10 |
Current Fiscal Year End Date |
Concept (Month/Day) |
For Period |
|
dei:CurrentFiscalYearEndDate |
| 11 |
Entity Common Stock, Shares Outstanding |
Concept (Shares) |
As Of |
|
dei:EntityCommonStockSharesOutstanding |
| 12 |
Entity Current Reporting Status |
Concept (Yes/No) |
For Period |
|
dei:EntityCurrentReportingStatus |
| 13 |
Document Fiscal Year Focus |
Concept (Year) |
For Period |
|
dei:DocumentFiscalYearFocus |
| 14 |
Document Fiscal Period Focus |
Concept (Fiscal Period) |
For Period |
|
dei:DocumentFiscalPeriodFocus |
| 15 |
Entity Emerging Growth Company |
Concept (Yes/No) |
For Period |
|
dei:EntityEmergingGrowthCompany |
| 16 |
Entity Filer Category |
Concept (Filer Category) |
For Period |
|
dei:EntityFilerCategory |
| 17 |
Entity Well-known Seasoned Issuer |
Concept (Yes/No) |
For Period |
|
dei:EntityWellKnownSeasonedIssuer |
| 18 |
Entity Ex Transition Period |
Concept (Yes/No) |
For Period |
|
dei:EntityExTransitionPeriod |
| 19 |
Entity Shell Company |
Concept (Yes/No) |
For Period |
|
dei:EntityShellCompany |
| 20 |
Entity Voluntary Filers |
Concept (Yes/No) |
For Period |
|
dei:EntityVoluntaryFilers |
| 21 |
002 - Statement - Consolidated Statements of Financial Position |
Network |
* |
* |
http://trilliumtherapeutics.com/role/BalanceSheet |
| 22 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 23 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 24 |
ASSETS |
Abstract |
|
|
ifrs-full:AssetsAbstract |
| 25 |
Current |
Abstract |
|
|
ifrs-full:CurrentAssetsAbstract |
| 26 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 27 |
Marketable securities |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentFinancialAssetsAtFairValueThroughProfitOrLossClassifiedAsHeldForTrading |
| 28 |
Amounts receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherCurrentReceivables |
| 29 |
Prepaid expenses |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentPrepaidExpenses |
| 30 |
Total current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CurrentAssets |
| 31 |
Property and equipment |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 32 |
Intangible assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 33 |
Other assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:OtherNoncurrentAssets |
| 34 |
Total non-current assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:NoncurrentAssets |
| 35 |
Total assets |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:Assets |
| 36 |
LIABILITIES |
Abstract |
|
|
ifrs-full:LiabilitiesAbstract |
| 37 |
Current |
Abstract |
|
|
ifrs-full:CurrentLiabilitiesAbstract |
| 38 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 39 |
Other current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherCurrentLiabilities |
| 40 |
Total current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentLiabilities |
| 41 |
Loan payable |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentPayables |
| 42 |
Deferred lease inducement |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent |
| 43 |
Other liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:OtherNoncurrentLiabilities |
| 44 |
Total non-current liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:NoncurrentLiabilities |
| 45 |
Total liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Liabilities |
| 46 |
EQUITY |
Abstract |
|
|
ifrs-full:EquityAbstract |
| 47 |
Common shares |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:IssuedCapital |
| 48 |
Series I preferred shares |
Concept (Monetary) |
As Of |
Credit |
tril:SeriesIPreferredShares |
| 49 |
Series II preferred shares |
Concept (Monetary) |
As Of |
Credit |
tril:SeriesIIPreferredShares |
| 50 |
Warrants |
Concept (Monetary) |
As Of |
Credit |
tril:Warrants |
| 51 |
Contributed surplus |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AdditionalPaidinCapital |
| 52 |
Deficit |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RetainedEarnings |
| 53 |
Total equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 54 |
Total liabilities and equity |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:EquityAndLiabilities |
| 55 |
003 - Statement - Consolidated Statements of Loss and Comprehensive Loss |
Network |
* |
* |
http://trilliumtherapeutics.com/role/IncomeStatement |
| 56 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 57 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 58 |
EXPENSES |
Abstract |
|
|
ifrs-full:ExpenseByNatureAbstract |
| 59 |
Research and development |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 60 |
General and administrative |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SellingGeneralAndAdministrativeExpense |
| 61 |
Operating expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OperatingExpense |
| 62 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 63 |
Finance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 64 |
Net foreign currency loss (gain) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss |
| 65 |
Net finance costs (income) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncomeCost |
| 66 |
Loss before income taxes |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ProfitLoss |
| 67 |
Current income tax expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CurrentTaxExpenseIncome |
| 68 |
Net loss and comprehensive loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 69 |
Basic and diluted loss per common share (in dollars per share) |
Concept (Share) |
For Period |
|
ifrs-full:BasicAndDilutedEarningsLossPerShare |
| 70 |
004 - Statement - Consolidated Statements of Changes in Equity |
Network |
* |
* |
http://trilliumtherapeutics.com/role/StockholdersEquity |
| 71 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 72 |
Components of equity [Axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 73 |
Equity [Domain] |
Member |
|
|
ifrs-full:EquityMember |
| 74 |
Common shares |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 75 |
Series I preferred shares |
Member |
|
|
tril:SeriesIPreferredSharesMember |
| 76 |
Series II preferred shares |
Member |
|
|
tril:SeriesIiPreferredSharesMember |
| 77 |
Warrants |
Member |
|
|
tril:WarrantsMember |
| 78 |
Contributed surplus |
Member |
|
|
ifrs-full:AdditionalPaidinCapitalMember |
| 79 |
Deficit |
Member |
|
|
ifrs-full:RetainedEarningsMember |
| 80 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 81 |
Beginning Balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 82 |
Beginning Balance (Shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesOutstanding |
| 83 |
Net loss and comprehensive loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 84 |
Shares issued, net of issue costs |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IssueOfEquity |
| 85 |
Shares issued, net of issue costs (Shares) |
Concept (Shares) |
For Period |
|
ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding |
| 86 |
Expiry of warrants |
Concept (Monetary) |
For Period |
Credit |
tril:IncreaseDecreaseThroughExpiryOfWarrants |
| 87 |
Conversion of DSUs from equity to cash settlement |
Concept (Monetary) |
For Period |
Debit |
tril:IncreaseDecreaseThroughConversionOfDeferredShareUnitsFromEquityToCashSettlement |
| 88 |
Exercise of warrants |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity |
| 89 |
Exercise of warrants (Shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandingThroughExerciseOfWarrantsEquity |
| 90 |
Exercise of stock options |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions |
| 91 |
Exercise of stock options (Shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandingThroughExerciseOfOptions |
| 92 |
Conversion of preferred shares |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments |
| 93 |
Conversion of preferred shares (Shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandinghroughConversionOfConvertibleInstruments |
| 94 |
Share-based compensation |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions |
| 95 |
Share-based compensation (Shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandingThroughSharebasedPaymentTransactions |
| 96 |
Total transactions with owners of the Company |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners |
| 97 |
Total transactions with owners of the Company (Shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandingThroughTransactionsWithOwners |
| 98 |
Ending Balance |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:Equity |
| 99 |
Ending Balance (Shares) |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesOutstanding |
| 100 |
005 - Statement - Consolidated Statements of Cash Flows |
Network |
* |
* |
http://trilliumtherapeutics.com/role/CashFlows |
| 101 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 102 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 103 |
OPERATING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract |
| 104 |
Net loss for the year |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 105 |
Adjustments for items not affecting cash |
Abstract |
|
|
ifrs-full:AdjustmentsForReconcileProfitLossAbstract |
| 106 |
Share-based compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForSharebasedPayments |
| 107 |
Interest accretion |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForInterestExpense |
| 108 |
Amortization of intangible assets |
Concept (Monetary) |
For Period |
Debit |
tril:AdjustmentsForAmortizationOfIntangibleAssets |
| 109 |
Depreciation of property and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense |
| 110 |
Deferred lease inducement |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome |
| 111 |
Change in fair value of contingent consideration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForFairValueGainsLosses |
| 112 |
Unrealized foreign exchange loss (gain) |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains |
| 113 |
Share issuance related to license amendment |
Concept (Monetary) |
For Period |
Debit |
tril:AdjustmentsForShareIssuanceRelatedToLicenseAmendment |
| 114 |
Adjustments for items not affecting cash |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital |
| 115 |
Changes in non-cash working capital balances |
Abstract |
|
|
tril:ChangesInNonCashWorkingCapitalBalancesAbstract |
| 116 |
Amounts receivable |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable |
| 117 |
Prepaid expenses |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets |
| 118 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable |
| 119 |
Other current liabilities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherCurrentLiabilities |
| 120 |
Cash used in operating activities |
Concept (Monetary) |
For Period |
|
ifrs-full:CashFlowsFromUsedInOperatingActivities |
| 121 |
INVESTING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract |
| 122 |
Net maturities (purchases) of marketable securities |
Concept (Monetary) |
For Period |
Credit |
tril:PaymentsToAcquireHeldToMaturityInvestments |
| 123 |
Purchase of property and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| 124 |
Cash provided by (used in) investing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInInvestingActivities |
| 125 |
FINANCING ACTIVITIES |
Abstract |
|
|
ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract |
| 126 |
Repayment of loan payable |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities |
| 127 |
Recognition of deferred lease inducement |
Concept (Monetary) |
For Period |
Credit |
tril:RecognitionOfDeferredLeaseInducement |
| 128 |
Issuance of share capital, net of issuance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ProceedsFromIssuingShares |
| 129 |
Cash provided by (used in) financing activities |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:CashFlowsFromUsedInFinancingActivities |
| 130 |
Impact of foreign exchange rate on cash and cash equivalents |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| 131 |
Net decrease in cash and cash equivalents during the year |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents |
| 132 |
Cash and cash equivalents, beginning of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 133 |
Cash and cash equivalents, end of year |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 134 |
Supplemental cash flow information |
Abstract |
|
|
tril:SupplementalCashFlowsInformationAbstract |
| 135 |
Preferred shares converted to common shares (note 9) |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments |
| 136 |
006 - Disclosure - Corporate information |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfCorporateInformationExplanatoryTextBlock |
| 137 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 138 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 139 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 140 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 141 |
Corporate information [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfCorporateInformationExplanatory |
| 142 |
007 - Disclosure - Basis of presentation |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfBasisOfPreparationOfFinancialStatementsExplanatoryTextBlock |
| 143 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 144 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 145 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 146 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 147 |
Basis of presentation [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory |
| 148 |
008 - Disclosure - Significant accounting policies |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryTextBlock |
| 149 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 150 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 151 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 152 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 153 |
Significant accounting policies [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory |
| 154 |
009 - Disclosure - Amounts receivable |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTextBlock |
| 155 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 156 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 157 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 158 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 159 |
Amounts receivable [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory |
| 160 |
010 - Disclosure - Property and equipment |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTextBlock |
| 161 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 162 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 163 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 164 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 165 |
Property and equipment [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory |
| 166 |
011 - Disclosure - Intangible assets |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTextBlock |
| 167 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 168 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 169 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 170 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 171 |
Intangible assets [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIntangibleAssetsExplanatory |
| 172 |
012 - Disclosure - Accounts payable and accrued liabilities |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherPayablesExplanatoryTextBlock |
| 173 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 174 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 175 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 176 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 177 |
Accounts payable and accrued liabilities [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory |
| 178 |
013 - Disclosure - Other liabilities |
Network |
* |
* |
http://trilliumtherapeutics.com/role/OtherLiabilities |
| 179 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 180 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 181 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 182 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 183 |
Other liabilities [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOtherNoncurrentLiabilitiesExplanatory |
| 184 |
014 - Disclosure - Share capital |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIssuedCapitalExplanatoryTextBlock |
| 185 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 186 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 187 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 188 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 189 |
Share capital [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIssuedCapitalExplanatory |
| 190 |
015 - Disclosure - Income taxes |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatoryTextBlock |
| 191 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 192 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 193 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 194 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 195 |
Income taxes [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfIncomeTaxExplanatory |
| 196 |
016 - Disclosure - Research and development |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfResearchAndDevelopmentExpenseExplanatoryTextBlock |
| 197 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 198 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 199 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 200 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 201 |
Research and development [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory |
| 202 |
017 - Disclosure - General and administrative |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfGeneralAndAdministrativeExpenseExplanatoryTextBlock |
| 203 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 204 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 205 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 206 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 207 |
General and administrative [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory |
| 208 |
018 - Disclosure - Commitments and contingencies |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfCommitmentsAndContingentLiabilitiesExplanatoryTextBlock |
| 209 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 210 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 211 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 212 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 213 |
Commitments and contingencies [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory |
| 214 |
019 - Disclosure - Related parties |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatoryTextBlock |
| 215 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 216 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 217 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 218 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 219 |
Related parties [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfRelatedPartyExplanatory |
| 220 |
020 - Disclosure - Operating segment |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfOperatingSegmentsExplanatoryTextBlock |
| 221 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 222 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 223 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 224 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 225 |
Operating segment [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfOperatingSegmentsExplanatory |
| 226 |
021 - Disclosure - Management of capital |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatoryTextBlock |
| 227 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 228 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 229 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 230 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 231 |
Management of capital [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory |
| 232 |
022 - Disclosure - Financial instruments |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfFinancialInstrumentsExplanatoryTextBlock |
| 233 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 234 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 235 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 236 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 237 |
Financial instruments [Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfFinancialInstrumentsExplanatory |
| 238 |
023 - Disclosure - Events after the balance sheet date |
Network |
* |
* |
http://trilliumtherapeutics.com/role/EventsAfterBalanceSheetDate |
| 239 |
Implied Table |
Table |
* |
* |
implied:Table |
| 240 |
Disclosure of non-adjusting events after reporting period [abstract] |
Abstract |
|
|
ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract |
| 241 |
Events after the balance sheet date [text block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory |
| 242 |
024 - Disclosure - Summary of Significant Accounting Policies (Policies) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies |
| 243 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 244 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 245 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 246 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 247 |
Basis of consolidation [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DescriptionOfAccountingPolicyForBasisOfConsolidationExplanatoryTextBlock |
| 248 |
Foreign currency [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory |
| 249 |
Cash and cash equivalents, and marketable securities [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory |
| 250 |
Property and equipment [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory |
| 251 |
Intangible assets [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory |
| 252 |
Impairment of non-financial assets [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory |
| 253 |
Provisions [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory |
| 254 |
Government assistance [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants |
| 255 |
Share-based compensation [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory |
| 256 |
Income taxes [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory |
| 257 |
Loss per share [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory |
| 258 |
Business combinations [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory |
| 259 |
New standards, amendments and interpretations adopted during 2018 [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DescriptionOfAccountingPolicyForNewStandardsAmendmentsAndInterpretationsAdoptedDuringTwoZeroOneSevenExplanatoryPolicyTextBlock |
| 260 |
New standards and interpretations not yet effective [Policy Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DescriptionOfOtherAccountingPoliciesRelevantToUnderstandingOfFinancialStatements |
| 261 |
025 - Disclosure - Significant accounting policies (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryTextBlockTables |
| 262 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 263 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 264 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 265 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 266 |
Disclosure of detailed information about estimated useful life or depreciation rate [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutEstimatedUsefulLifeOrDepreciationRateExplanatory |
| 267 |
026 - Disclosure - Amounts receivable (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTextBlockTables |
| 268 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 269 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 270 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 271 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 272 |
Disclosure of detailed information about trade and other receivables [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory |
| 273 |
027 - Disclosure - Property and equipment (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfPropertyPlantAndEquipmentExplanatoryTextBlockTables |
| 274 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 275 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 276 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 277 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 278 |
Disclosure of detailed information about property, plant and equipment [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory |
| 279 |
028 - Disclosure - Intangible assets (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIntangibleAssetsExplanatoryTextBlockTables |
| 280 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 281 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 282 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 283 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 284 |
Disclosure of detailed information about intangible assets [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory |
| 285 |
Disclosure of detailed information about the acquisition of Fluorinov [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory |
| 286 |
Disclosure of detailed information about cash used in acquisition [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutCashUsedInAcquisitionExplanatoryTableTextBlock |
| 287 |
029 - Disclosure - Accounts payable and accrued liabilities (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherPayablesExplanatoryTextBlockTables |
| 288 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 289 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 290 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 291 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 292 |
Disclosure of detailed information about trade and other payables [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatory |
| 293 |
030 - Disclosure - Share capital (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIssuedCapitalExplanatoryTextBlockTables |
| 294 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 295 |
Components of equity [Axis] |
Axis |
|
|
ifrs-full:ComponentsOfEquityAxis |
| 296 |
Equity [Domain] |
Member |
|
|
ifrs-full:EquityMember |
| 297 |
Preferred Warrants [Member] |
Member |
|
|
tril:PreferredWarrantsMember |
| 298 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 299 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 300 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 301 |
Disclosure of detailed information about warrants outstanding [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutWarrantsOutstandingExplanatory |
| 302 |
Disclosure of detailed information about warrants, activity [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutWarrantsActivityExplanatory |
| 303 |
Disclosure of number and weighted average exercise prices of share options [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory |
| 304 |
Disclosure of number and weighted average remaining contractual life of outstanding share options [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory |
| 305 |
Disclosure of detailed information about options, valuation assumptions [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutOptionsValuationAssumptionsExplanatory |
| 306 |
031 - Disclosure - Income taxes (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfIncomeTaxExplanatoryTextBlockTables |
| 307 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 308 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 309 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 310 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 311 |
Disclosure of deferred tax assets not recognized [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfUnusedTaxCreditsExplanatory |
| 312 |
Disclosure of non-capital tax losses expiry [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfUnusedTaxLossesExplanatory |
| 313 |
Disclosure of reconciliation of the Canadian statutory income tax rate [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutEffectiveIncomeTaxExpenseRecoveryExplanatory |
| 314 |
032 - Disclosure - Research and development (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfResearchAndDevelopmentExpenseExplanatoryTextBlockTables |
| 315 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 316 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 317 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 318 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 319 |
Disclosure of detailed information about research and development expenses [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
tril:DisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatory |
| 320 |
033 - Disclosure - General and administrative (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfGeneralAndAdministrativeExpenseExplanatoryTextBlockTables |
| 321 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 322 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 323 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 324 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 325 |
Disclosure of expenses by nature [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfExpensesByNatureExplanatory |
| 326 |
034 - Disclosure - Related parties (Tables) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/NotesToFinancialStatementsDisclosureOfRelatedPartyExplanatoryTextBlockTables |
| 327 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 328 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 329 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 330 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 331 |
Disclosure of information about key management personnel [Table Text Block] |
Concept (Text Block (HTML)) |
For Period |
|
ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory |
| 332 |
035 - Disclosure - Significant accounting policies (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryDetails |
| 333 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 334 |
Components of cash and cash equivalents [Axis] |
Axis |
|
|
tril:ComponentsOfCashAndCashEquivalentsAxis |
| 335 |
Components of cash and cash equivalents [Domain] |
Member |
|
|
tril:ComponentsOfCashAndCashEquivalentsDomain |
| 336 |
Guaranteed investment certificates [Member] |
Member |
|
|
tril:GuaranteedInvestmentCertificatesMember |
| 337 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 338 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 339 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 340 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 341 |
Investment maturity |
Concept (Decimal) |
As Of |
|
tril:InvestmentMaturity |
| 342 |
036 - Disclosure - Intangible assets (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/IntangibleAssetsNarrativeDetails |
| 343 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 344 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 345 |
Carrying amount [Domain] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 346 |
Amortization |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 347 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 348 |
Reduction to the amortization charge |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncreaseDecreaseInIntangibleAssetsAndGoodwill |
| 349 |
037 - Disclosure - Other liabilities (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfOtherNoncurrentLiabilitiesExplanatoryDetails |
| 350 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 351 |
Business combinations [Axis] |
Axis |
|
|
ifrs-full:BusinessCombinationsAxis |
| 352 |
Business combinations [Domain] |
Member |
|
|
ifrs-full:BusinessCombinationsMember |
| 353 |
Aquisition of Fluorinov [Member] |
Member |
|
|
tril:AquisitionOfFluorinovMember |
| 354 |
Borrowings by name [Axis] |
Axis |
|
|
ifrs-full:BorrowingsByNameAxis |
| 355 |
Borrowings by name [Domain] |
Member |
|
|
ifrs-full:BorrowingsByNameMember |
| 356 |
Federal Economic Development Agency for Southern Ontario [Member] |
Member |
|
|
tril:FederalEconomicDevelopmentAgencyForSouthernOntarioMember |
| 357 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 358 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 359 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 360 |
Monthly repayments |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:RepaymentsOfNoncurrentBorrowings |
| 361 |
Non-interest bearing contribution agreement |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LoansReceived |
| 362 |
Market interest rate |
Concept (Percent) |
As Of |
|
ifrs-full:BorrowingsInterestRate |
| 363 |
Deferred lease inducement |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent |
| 364 |
Contingent consideration |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:ContingentLiabilitiesIncurredInRelationToInterestsInAssociates |
| 365 |
Reduction in fair value of contingent consideration |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdjustmentsForFairValueGainsLosses |
| 366 |
038 - Disclosure - Share capital (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfIssuedCapitalExplanatoryDetails |
| 367 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 368 |
Beneficial ownership limitations, preferred share conversions [Axis] |
Axis |
|
|
tril:BeneficialOwnershipLimitationsPreferredShareConversionsAxis |
| 369 |
Beneficial ownership limitations, preferred share conversions [Domain] |
Member |
|
|
tril:BeneficialOwnershipLimitationsPreferredShareConversionsDomain |
| 370 |
Default maximum beneficial ownership [Member] |
Member |
|
|
tril:DefaultMaximumBeneficialOwnershipMember |
| 371 |
Maximum beneficial ownership with 61 days prior written notice [Member] |
Member |
|
|
tril:MaximumBeneficialOwnershipWithSixOneDaysPriorWrittenNoticeMember |
| 372 |
Maximum beneficial ownership with clearance of personal information form by the TSX [Member] |
Member |
|
|
tril:MaximumBeneficialOwnershipWithClearanceOfPersonalInformationFormByTheTsxMember |
| 373 |
Minimum beneficial ownership upon approval of TSX and shareholders [Member] |
Member |
|
|
tril:MinimumBeneficialOwnershipUponApprovalOfTsxAndShareholdersMember |
| 374 |
Types of shares [Axis] |
Axis |
|
|
tril:TypesOfSharesAxis |
| 375 |
Types of shares [Domain] |
Member |
|
|
tril:TypesOfSharesDomain |
| 376 |
Common shares [Member] |
Member |
|
|
ifrs-full:IssuedCapitalMember |
| 377 |
Series II Non-Voting Convertible First Preferred Shares [Member] |
Member |
|
|
tril:SeriesIiNonvotingConvertibleFirstPreferredSharesMember |
| 378 |
Series I First Preferred Shares [Member] |
Member |
|
|
tril:SeriesIFirstPreferredSharesMember |
| 379 |
Series II First Preferred Shares [Member] |
Member |
|
|
tril:SeriesIiFirstPreferredSharesMember |
| 380 |
Series I and II First Preferred Shares [Member] |
Member |
|
|
tril:SeriesIAndIiFirstPreferredSharesMember |
| 381 |
Components of research and development [Axis] |
Axis |
|
|
tril:ComponentsOfResearchAndDevelopmentAxis |
| 382 |
Components of research and development [Domain] |
Member |
|
|
tril:ComponentsOfResearchAndDevelopmentDomain |
| 383 |
License Agreement Amendment [Member] |
Member |
|
|
tril:LicenseAgreementAmendmentMember |
| 384 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 385 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 386 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 387 |
Beneficial ownership of outstanding common shares |
Concept (Percent) |
For Period |
|
tril:BeneficialOwnershipOfOutstandingCommonShares |
| 388 |
Number of shares issued during period |
Concept (Shares) |
For Period |
|
tril:NumberOfSharesIssuedDuringPeriod |
| 389 |
Price per share |
Concept (Share) |
For Period |
|
tril:PricePerShare |
| 390 |
Proceeds from issue of share capital including offering expenses |
Concept (Monetary) |
For Period |
Debit |
tril:ProceedsFromIssuingSharesIncludingOfferingExpenses |
| 391 |
Offering expenses |
Concept (Monetary) |
For Period |
Debit |
tril:OfferingExpenses |
| 392 |
Warrants amended, number of common shares available on exercise |
Concept (Shares) |
For Period |
|
tril:WarrantsAmendedNumberOfCommonSharesAvailableOnExercise |
| 393 |
Warrants amended, previous exercise price |
Concept (Share) |
For Period |
|
tril:WarrantsAmendedPreviousExercisePrice |
| 394 |
Exercise of warrants (shares) |
Concept (Shares) |
For Period |
|
tril:IncreaseDecreaseInNumberOfSharesOutstandingThroughExerciseOfWarrantsEquity |
| 395 |
Warrants exercised |
Concept (Decimal) |
For Period |
|
tril:WarrantsExercised |
| 396 |
Proceeds from warrants exercised |
Concept (Monetary) |
For Period |
Debit |
tril:ProceedsFromWarrantsExercised |
| 397 |
Preferred shares converted |
Concept (Shares) |
For Period |
|
tril:PreferredSharesConverted |
| 398 |
Common shares issued from conversion of preferred shares |
Concept (Shares) |
For Period |
|
tril:CommonSharesIssuedFromConversionOfPreferredShares |
| 399 |
Weighted average number of ordinary shares outstanding |
Concept (Shares) |
For Period |
|
ifrs-full:WeightedAverageShares |
| 400 |
Total shares available for issuance under 2018 Stock Option Plan |
Concept (Shares) |
As Of |
|
tril:TotalSharesAvailableForIssuanceUnderTwoZeroOneEightStockOptionPlan |
| 401 |
Shares available for issuance |
Concept (Shares) |
As Of |
|
tril:SharesAvailableForIssuance |
| 402 |
Shares remaining for issuance |
Concept (Shares) |
As Of |
|
tril:SharesRemainingForIssuance |
| 403 |
Share options granted |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 404 |
Fair value of stock options issued |
Concept (Monetary) |
For Period |
Credit |
tril:FairValueOfStockOptionsIssued |
| 405 |
Weighted average grant date fair value |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageSharePriceShareOptionsGranted |
| 406 |
Total shares available for issuance under 2014 DSU Plan |
Concept (Shares) |
As Of |
|
tril:TotalSharesAvailableForIssuanceUnderTwoZeroOneFourDeferredShareUnitPlan |
| 407 |
Units available for issuance |
Concept (Shares) |
As Of |
|
tril:UnitsAvailableForIssuance |
| 408 |
Conversion of DSUs from equity to cash settlement |
Concept (Monetary) |
For Period |
Debit |
tril:IncreaseDecreaseThroughConversionOfDeferredShareUnitsFromEquityToCashSettlement |
| 409 |
Units issued |
Concept (Shares) |
For Period |
|
tril:UnitsGranted |
| 410 |
Units outstanding |
Concept (Shares) |
As Of |
|
tril:UnitsOutstanding |
| 411 |
Fair value of units granted |
Concept (Monetary) |
As Of |
Credit |
tril:FairValueOfUnitsGranted |
| 412 |
Payment to licensors |
Concept (Monetary) |
For Period |
Debit |
tril:PaymentToLicensors |
| 413 |
Shares issued, net of issue costs (Shares) |
Concept (Shares) |
For Period |
|
ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding |
| 414 |
039 - Disclosure - Income taxes (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfIncomeTaxExplanatoryDetails |
| 415 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 416 |
Components of unrecognized deferred tax assets [Axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 417 |
Components of unrecognized deferred tax assets [Domain] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 418 |
Research and development expenditures [Member] |
Member |
|
|
tril:ResearchAndDevelopmentExpendituresMember |
| 419 |
Unclaimed Canadian scientific research and development tax credits [Member] |
Member |
|
|
tril:UnclaimedCanadianScientificResearchAndDevelopmentTaxCreditsMember |
| 420 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 421 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 422 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 423 |
Unused research and development expenses for income tax purposes |
Concept (Monetary) |
As Of |
Debit |
tril:UnusedResearchAndDevelopmentExpensesForIncomeTaxPurposes |
| 424 |
Unclaimed scientific research and development tax credits |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised |
| 425 |
040 - Disclosure - Commitments and contingencies (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfCommitmentsAndContingentLiabilitiesExplanatoryDetails |
| 426 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 427 |
Items of contingent liabilities [Axis] |
Axis |
|
|
ifrs-full:ItemsOfContingentLiabilitiesAxis |
| 428 |
Items of contingent liabilities [Domain] |
Member |
|
|
ifrs-full:ItemsOfContingentLiabilitiesMember |
| 429 |
License agreement for SIRPaFc [Member] |
Member |
|
|
tril:LicenseAgreementForSIRPaFcMember |
| 430 |
Fluorinov [Member] |
Member |
|
|
tril:FluorinovMember |
| 431 |
Catalent Pharma Solutions [Member] |
Member |
|
|
tril:CatalentPharmaSolutionsMember |
| 432 |
Classes of contingent liabilities [Axis] |
Axis |
|
|
ifrs-full:ClassesOfContingentLiabilitiesAxis |
| 433 |
Contingent liabilities [Domain] |
Member |
|
|
ifrs-full:ContingentLiabilitiesMember |
| 434 |
Successful patent grants [Member] |
Member |
|
|
tril:SuccessfulPatentGrantsMember |
| 435 |
First patient dosed in phase 2 trials |
Member |
|
|
tril:FirstPatientDosedInPhaseIiTrialsMember |
| 436 |
First patient dosed in phase 3 trials |
Member |
|
|
tril:FirstPatientDosedInPhaseIiiTrialsMember |
| 437 |
Regulatory [Member] |
Member |
|
|
tril:RegulatoryMember |
| 438 |
Pre-marketing approval milestones [Member] |
Member |
|
|
tril:PremarketingApprovalMilestonesMember |
| 439 |
Sales milestones [Member] |
Member |
|
|
tril:SalesMilestonesMember |
| 440 |
Categories of related parties [Axis] |
Axis |
|
|
ifrs-full:CategoriesOfRelatedPartiesAxis |
| 441 |
Related parties [Domain] |
Member |
|
|
ifrs-full:RelatedPartiesMember |
| 442 |
One individual company director [Member] |
Member |
|
|
tril:OneIndividualCompanyDirectorMember |
| 443 |
Range [Axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 444 |
Ranges [Domain] |
Member |
|
|
ifrs-full:RangesMember |
| 445 |
Over the next 12 months [Member] |
Member |
|
|
ifrs-full:NotLaterThanOneYearMember |
| 446 |
12 to 60 months [Member] |
Member |
|
|
ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember |
| 447 |
Later than 60 months [Member] |
Member |
|
|
ifrs-full:LaterThanFiveYearsMember |
| 448 |
Bottom of range [Member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 449 |
Top of range [Member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 450 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 451 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 452 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 453 |
Commitments |
Concept (Monetary) |
As Of |
Credit |
tril:Commitments |
| 454 |
Operating lease commitments |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:LeaseLiabilities |
| 455 |
Percentage of contingent future payments satisfied through issuance of common shares |
Concept (Percent) |
As Of |
|
tril:PercentageOfContingentFuturePaymentsSatisfiedThroughIssuanceOfCommonShares |
| 456 |
Contingent future payments satisfied through issuance of common shares limit |
Concept (Shares) |
As Of |
|
tril:ContingentFuturePaymentsSatisfiedThroughIssuanceOfCommonSharesLimit |
| 457 |
Net central nervous system asset proceeds to share with Fluorinov shareholders |
Concept (Percent) |
As Of |
|
tril:NetCentralNervousSystemAssetProceedsToShareWithFluorinovShareholders |
| 458 |
Ownership percentage maximum |
Concept (Percent) |
As Of |
|
tril:OwnershipPercentageMaximum |
| 459 |
041 - Disclosure - Related parties (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfRelatedPartyExplanatoryDetails |
| 460 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 461 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 462 |
Proportion of voting rights held by key management personnel |
Concept (Percent) |
As Of |
|
tril:ProportionOfVotingRightsHeldByKeyManagementPersonnel |
| 463 |
Amount payable to director for consulting fees |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:AmountsPayableRelatedPartyTransactions |
| 464 |
042 - Disclosure - Financial instruments (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfFinancialInstrumentsExplanatoryDetails |
| 465 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 466 |
Types of risks [Axis] |
Axis |
|
|
ifrs-full:TypesOfRisksAxis |
| 467 |
Risks [Domain] |
Member |
|
|
ifrs-full:TypesOfRisksMember |
| 468 |
Interest rate risk [Member] |
Member |
|
|
ifrs-full:InterestRateRiskMember |
| 469 |
Currency risk [Member] |
Member |
|
|
ifrs-full:CurrencyRiskMember |
| 470 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 471 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 472 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 473 |
Finance income |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:FinanceIncome |
| 474 |
Value at risk, sensitivity basis points |
Concept (Decimal) |
For Period |
|
tril:ValueAtRiskSensitivityBasisPoints |
| 475 |
Cash and cash equivalents |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:CashAndCashEquivalents |
| 476 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherPayables |
| 477 |
Value at risk, sensitivity percentage |
Concept (Percent) |
For Period |
|
tril:ValueAtRiskSensitivityPercentage |
| 478 |
Finance costs |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:FinanceCosts |
| 479 |
Operating expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:OperatingExpense |
| 480 |
Net loss |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:ComprehensiveIncome |
| 481 |
043 - Disclosure - Events after the balance sheet date (Narrative) (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/EventsAfterBalanceSheetDateNarrativeDetails |
| 482 |
Disclosure of non-adjusting events after reporting period [table] |
Table |
* |
* |
ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable |
| 483 |
Non-adjusting events after reporting period [axis] |
Axis |
|
|
ifrs-full:NonadjustingEventsAfterReportingPeriodAxis |
| 484 |
Non-adjusting events after reporting period [member] |
Member |
|
|
ifrs-full:NonadjustingEventsMember |
| 485 |
Major ordinary share transactions [member] |
Member |
|
|
ifrs-full:MajorOrdinaryShareTransactionsMember |
| 486 |
Classes of share capital [axis] |
Axis |
|
|
ifrs-full:ClassesOfShareCapitalAxis |
| 487 |
Share capital [member] |
Member |
|
|
ifrs-full:ClassesOfShareCapitalMember |
| 488 |
Common share |
Member |
|
|
ifrs-full:OrdinarySharesMember |
| 489 |
Series II Non-Voting Convertible First Preferred Share |
Member |
|
|
tril:SeriesTwoNonVotingConvertibleFirstPreferredShareMember |
| 490 |
Disclosure of non-adjusting events after reporting period [line items] |
LineItems |
|
|
ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems |
| 491 |
Proceeds from gross offering |
Concept (Monetary) |
For Period |
Debit |
tril:ProceedsFromGrossOffering |
| 492 |
Number of units issued |
Concept (Shares) |
As Of |
|
ifrs-full:NumberOfSharesIssued |
| 493 |
Share and warrant description |
Concept (Text/String) |
For Period |
|
tril:ShareAndWarrantDescription |
| 494 |
Issue price per unit |
Concept (Share) |
As Of |
|
ifrs-full:ParValuePerShare |
| 495 |
Exercise price |
Concept (Share) |
As Of |
|
tril:ExercisePriceOfCommonShareToPurchaseWarrant |
| 496 |
Term of warrant to purchase |
Concept (xbrli:durationItemType) |
For Period |
|
tril:TermOfWarrantToPurchase |
| 497 |
044 - Disclosure - Disclosure of detailed information about estimated useful life or depreciation rate (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutEstimatedUsefulLifeOrDepreciationRateExplanatoryDetails |
| 498 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 499 |
Classes of assets [Axis] |
Axis |
|
|
ifrs-full:ClassesOfAssetsAxis |
| 500 |
Assets [Domain] |
Member |
|
|
ifrs-full:ClassesOfAssetsMember |
| 501 |
Lab equipment |
Member |
|
|
tril:LabEquipmentMember |
| 502 |
Computer equipment |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 503 |
Office equipment |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 504 |
Leaseholds |
Member |
|
|
ifrs-full:LeaseholdImprovementsMember |
| 505 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 506 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 507 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 508 |
Useful lives or depreciation rates, property, plant and equipment |
Concept (Text/String) |
For Period |
|
ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment |
| 509 |
Depreciation method, property, plant and equipment |
Concept (Text/String) |
For Period |
|
ifrs-full:DepreciationMethodPropertyPlantAndEquipment |
| 510 |
045 - Disclosure - Disclosure of detailed information about trade and other receivables (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryDetails |
| 511 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 512 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 513 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 514 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 515 |
Government receivable |
Concept (Monetary) |
As Of |
Debit |
tril:GovernmentReceivable |
| 516 |
Interest receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:InterestReceivable |
| 517 |
Amounts receivable |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:TradeAndOtherCurrentReceivables |
| 518 |
046 - Disclosure - Disclosure of detailed information about property, plant and equipment (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatoryDetails |
| 519 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 520 |
Classes of property, plant and equipment [Axis] |
Axis |
|
|
ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis |
| 521 |
Property, plant and equipment [Domain] |
Member |
|
|
ifrs-full:PropertyPlantAndEquipmentMember |
| 522 |
Lab equipment [Member] |
Member |
|
|
tril:LabEquipmentMember |
| 523 |
Computer equipment [Member] |
Member |
|
|
ifrs-full:ComputerEquipmentMember |
| 524 |
Office equipment and leaseholds |
Member |
|
|
ifrs-full:OfficeEquipmentMember |
| 525 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 526 |
Carrying amount [Domain] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 527 |
Cost [Member] |
Member |
|
|
ifrs-full:AtCostMember |
| 528 |
Accumulated depreciation [Member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 529 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 530 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 531 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 532 |
Property, plant and equipment, Beginning Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 533 |
Additions other than through business combinations, property, plant and equipment |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment |
| 534 |
Depreciation, property, plant and equipment |
Concept (Monetary) |
For Period |
|
ifrs-full:DepreciationPropertyPlantAndEquipment |
| 535 |
Disposals, property, plant and equipment |
Concept (Monetary) |
For Period |
Credit |
ifrs-full:DisposalsPropertyPlantAndEquipment |
| 536 |
Property, plant and equipment, Ending Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:PropertyPlantAndEquipment |
| 537 |
047 - Disclosure - Disclosure of detailed information about intangible assets (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutIntangibleAssetsExplanatoryDetails |
| 538 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 539 |
Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Axis] |
Axis |
|
|
ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis |
| 540 |
Carrying amount [Domain] |
Member |
|
|
ifrs-full:CarryingAmountMember |
| 541 |
Cost [Member] |
Member |
|
|
ifrs-full:AtCostMember |
| 542 |
Accumulated depreciation [Member] |
Member |
|
|
ifrs-full:AccumulatedDepreciationAndAmortisationMember |
| 543 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 544 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 545 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 546 |
Intangible assets, Beginning Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 547 |
Amortization |
Concept (Monetary) |
For Period |
|
ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill |
| 548 |
Intangible assets, Ending Balance |
Concept (Monetary) |
As Of |
Debit |
ifrs-full:IntangibleAssetsOtherThanGoodwill |
| 549 |
048 - Disclosure - Disclosure of detailed information about trade and other payables (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryDetails |
| 550 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 551 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 552 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 553 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 554 |
Trade and other payables |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers |
| 555 |
Accrued liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities |
| 556 |
Due to related parties |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties |
| 557 |
Accounts payable and accrued liabilities |
Concept (Monetary) |
As Of |
Credit |
ifrs-full:TradeAndOtherCurrentPayables |
| 558 |
049 - Disclosure - Disclosure of detailed information about warrants, activity (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutWarrantsActivityExplanatoryDetails |
| 559 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 560 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 561 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 562 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 563 |
Balance, beginning of year |
Concept (Decimal) |
As Of |
|
tril:WarrantsOutstanding |
| 564 |
Weighted average exercise price, beginning of year |
Concept (Monetary) |
As Of |
Debit |
tril:WeightedAverageExercisePriceOfWarrantsOutstanding |
| 565 |
Warrant amendment |
Concept (Decimal) |
For Period |
|
tril:WarrantsAmended |
| 566 |
Warrant amendment, Weighted average exercise price |
Concept (Monetary) |
For Period |
Debit |
tril:WeightedAverageExercisePriceOfWarrantsAmended |
| 567 |
Exercised |
Concept (Decimal) |
For Period |
|
tril:WarrantsExercised |
| 568 |
Warrants exercised, Weighted average exercise price |
Concept (Monetary) |
For Period |
Debit |
tril:WeightedAverageExercisePriceOfWarrantsExercised |
| 569 |
Warrants expired |
Concept (Decimal) |
For Period |
|
tril:WarrantsExpired |
| 570 |
Weighted average exercise price of warrants expired |
Concept (Monetary) |
For Period |
|
tril:WeightedAverageExercisePriceOfWarrantsExpired |
| 571 |
Balance, end of year |
Concept (Decimal) |
As Of |
|
tril:WarrantsOutstanding |
| 572 |
Weighted average exercise price, end of year |
Concept (Monetary) |
As Of |
Debit |
tril:WeightedAverageExercisePriceOfWarrantsOutstanding |
| 573 |
050 - Disclosure - Disclosure of number and weighted average exercise prices of share options (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatoryDetails |
| 574 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 575 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 576 |
Balance, beginning of year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 577 |
Weighted average exercise price, beginning of year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 578 |
Share options granted |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 579 |
Granted, weighted average exercise price |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement |
| 580 |
Forfeited |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 581 |
Forfeited, weighted average exercise price |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement |
| 582 |
Expired |
Concept (Decimal) |
For Period |
|
ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 583 |
Expired, weighted average exercise price |
Concept (Monetary) |
For Period |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement |
| 584 |
Balance, end of year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 585 |
Weighted average exercise price, end of year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 586 |
Options exercisable, end of year |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 587 |
Options exercisable, weighted average exercise price, end of year |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 588 |
051 - Disclosure - Disclosure of number and weighted average remaining contractual life of outstanding share options (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatoryDetails |
| 589 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 590 |
Ranges of exercise prices for outstanding share options [Axis] |
Axis |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis |
| 591 |
Ranges of exercise prices for outstanding share options [Domain] |
Member |
|
|
ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember |
| 592 |
Exercise prices, $3.90 - $4.23 |
Member |
|
|
tril:ExercisePricesThreeNineZeroFourTwoThreeMember |
| 593 |
Exercise prices, $6.36 - $9.89 [Member] |
Member |
|
|
tril:ExercisePricesSixThreeSixNineEightNineMember |
| 594 |
Exercise prices, $10.35 - $12.22 [Member] |
Member |
|
|
tril:ExercisePricesOneZeroThreeFiveOneTwoTwoTwoMember |
| 595 |
Exercise prices, $13.98 - $15.30 [Member] |
Member |
|
|
tril:ExercisePricesOneThreeNineEightOneFiveThreeZeroMember |
| 596 |
Exercise prices, $17.00 - $23.44 [Member] |
Member |
|
|
tril:ExercisePricesOneSevenZeroZeroTwoThreeFourFourMember |
| 597 |
Exercise price, $28.05 [Member] |
Member |
|
|
tril:ExercisePriceTwoEightZeroFiveMember |
| 598 |
Range [Axis] |
Axis |
|
|
ifrs-full:RangeAxis |
| 599 |
Ranges [Domain] |
Member |
|
|
ifrs-full:RangesMember |
| 600 |
Bottom of range [Member] |
Member |
|
|
ifrs-full:BottomOfRangeMember |
| 601 |
Top of range [Member] |
Member |
|
|
ifrs-full:TopOfRangeMember |
| 602 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 603 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 604 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 605 |
Exercise price of outstanding share options |
Concept (Monetary) |
As Of |
|
ifrs-full:ExercisePriceOfOutstandingShareOptions |
| 606 |
Number outstanding |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfOutstandingShareOptions |
| 607 |
Weighted average remaining contractual life (in years) |
Concept (Decimal) |
As Of |
|
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions |
| 608 |
Weighted average exercise price |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement |
| 609 |
Number exercisable |
Concept (Decimal) |
As Of |
|
ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 610 |
Weighted average exercise price |
Concept (Monetary) |
As Of |
|
ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement |
| 611 |
052 - Disclosure - Disclosure of detailed information about options, valuation assumptions (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutOptionsValuationAssumptionsExplanatoryDetails |
| 612 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 613 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 614 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 615 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 616 |
Expected option life (years) |
Concept (Decimal) |
For Period |
|
ifrs-full:DescriptionOfOptionLifeShareOptionsGranted |
| 617 |
Risk-free interest rate |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted |
| 618 |
Dividend yield |
Concept (Percent) |
For Period |
|
ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted |
| 619 |
Expected volatility |
Concept (Percent) |
For Period |
|
ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted |
| 620 |
053 - Disclosure - Disclosure of deferred tax assets not recognized (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfUnusedTaxCreditsExplanatoryDetails |
| 621 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 622 |
Components of unrecognized deferred tax assets [Axis] |
Axis |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis |
| 623 |
Components of unrecognized deferred tax assets [Domain] |
Member |
|
|
ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember |
| 624 |
Non-capital losses carried forward [Member] |
Member |
|
|
tril:NoncapitalLossesCarriedForwardMember |
| 625 |
Tax credits carried forward [Member] |
Member |
|
|
tril:TaxCreditsCarriedForwardMember |
| 626 |
Accounting basis of property and equipment and intangible assets in excess of tax basis [Member] |
Member |
|
|
tril:AccountingBasisOfPropertyAndEquipmentAndIntangibleAssetsInExcessOfTaxBasisMember |
| 627 |
Scientific research and experimental development expenditures [Member] |
Member |
|
|
tril:ScientificResearchAndExperimentalDevelopmentExpendituresMember |
| 628 |
Share issue costs and other [Member] |
Member |
|
|
tril:ShareIssueCostsAndOtherMember |
| 629 |
Deferred tax assets before Fluorinov acquisition [Member] |
Member |
|
|
tril:DeferredTaxAssetsBeforeFluorinovAcquisitionMember |
| 630 |
Fluorinov acquisition [Member] |
Member |
|
|
tril:LessAmountRecognizedOnFluorinovAcquisitionMember |
| 631 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 632 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 633 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 634 |
Unrecognized deferred tax assets |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised |
| 635 |
054 - Disclosure - Disclosure of non-capital tax losses expiry (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfUnusedTaxLossesExplanatoryDetails |
| 636 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 637 |
Noncapital Tax Losses Expiry Years [Axis] |
Axis |
|
|
tril:NoncapitalTaxLossesExpiryYearsAxis |
| 638 |
Noncapital Tax Losses Expiry Years [Domain] |
Member |
|
|
tril:NoncapitalTaxLossesExpiryYearsDomain |
| 639 |
Expiry in 2025 [Member] |
Member |
|
|
tril:TwoZeroTwoFiveMember |
| 640 |
Expiry in 2026 [Member] |
Member |
|
|
tril:TwoZeroTwoSixMember |
| 641 |
Expiry in 2027 [Member] |
Member |
|
|
tril:TwoZeroTwoSevenMember |
| 642 |
Expiry in 2028 [Member] |
Member |
|
|
tril:TwoZeroTwoEightMember |
| 643 |
Expiry in 2029 [Member] |
Member |
|
|
tril:TwoZeroTwoNineMember |
| 644 |
Expiry in 2030 [Member] |
Member |
|
|
tril:TwoZeroThreeZeroMember |
| 645 |
Expiry in 2031 [Member] |
Member |
|
|
tril:TwoZeroThreeOneMember |
| 646 |
Expiry in 2032 [Member] |
Member |
|
|
tril:TwoZeroThreeTwoMember |
| 647 |
Expiry in 2033 [Member] |
Member |
|
|
tril:TwoZeroThreeThreeMember |
| 648 |
Expiry in 2034 [Member] |
Member |
|
|
tril:TwoZeroThreeFourMember |
| 649 |
Expiry in 2035 [Member] |
Member |
|
|
tril:TwoZeroThreeFiveMember |
| 650 |
Expiry in 2036 [Member] |
Member |
|
|
tril:TwoZeroThreeSixMember |
| 651 |
Expiry in 2037 [Member] |
Member |
|
|
tril:ExpiryInTwoZeroThreeSevenMember |
| 652 |
Expiry in 2038 [Member] |
Member |
|
|
tril:ExpiryInTwoZeroThreeEightMember |
| 653 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 654 |
Non-capital tax losses |
Concept (Monetary) |
As Of |
|
ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised |
| 655 |
055 - Disclosure - Disclosure of reconciliation of the Canadian statutory income tax rate (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutEffectiveIncomeTaxExpenseRecoveryExplanatoryDetails |
| 656 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 657 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 658 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 659 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 660 |
Statutory income tax rate |
Concept (Percent) |
For Period |
|
ifrs-full:ApplicableTaxRate |
| 661 |
Income tax recovery based on statutory income tax rate |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:TaxExpenseIncomeAtApplicableTaxRate |
| 662 |
Investment tax credits |
Concept (Monetary) |
For Period |
Credit |
tril:TaxEffectOfInvestmentTaxCredits |
| 663 |
Share-based compensation and other |
Concept (Monetary) |
For Period |
Debit |
tril:TaxEffectOfTaxShareBasedCompensationAndOther |
| 664 |
Change in unrecognized tax assets |
Concept (Monetary) |
For Period |
Debit |
tril:TaxEffectOfChangeInUnrecognizedTaxAssets |
| 665 |
Income tax expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:IncomeTaxExpenseContinuingOperations |
| 666 |
056 - Disclosure - Disclosure of detailed information about research and development expenses (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfDetailedInformationAboutResearchAndDevelopmentExpensesExplanatoryDetails |
| 667 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 668 |
Components of research and development [Axis] |
Axis |
|
|
tril:ComponentsOfResearchAndDevelopmentAxis |
| 669 |
Components of research and development [Domain] |
Member |
|
|
tril:ComponentsOfResearchAndDevelopmentDomain |
| 670 |
Research and development programs, excluding the below items |
Member |
|
|
tril:ResearchAndDevelopmentProgramsExcludingTheBelowItemsMember |
| 671 |
Salaries, fees and short-term benefits |
Member |
|
|
tril:SalariesFeesAndShorttermBenefitsMember |
| 672 |
License agreement amendment (note 9(b)) |
Member |
|
|
tril:LicenseAgreementAmendmentMember |
| 673 |
Share-based compensation |
Member |
|
|
tril:SharebasedCompensationMember |
| 674 |
Amortization of intangible assets |
Member |
|
|
tril:AmortizationOfIntangibleAssetsMember |
| 675 |
Change in fair value of contingent consideration |
Member |
|
|
tril:FairValueRemeasurementOfContingentConsiderationMember |
| 676 |
Depreciation of property and equipment |
Member |
|
|
tril:DepreciationOfPropertyAndEquipmentMember |
| 677 |
Tax credits |
Member |
|
|
tril:TaxCreditsMember |
| 678 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 679 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 680 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 681 |
Research and development expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:ResearchAndDevelopmentExpense |
| 682 |
057 - Disclosure - Disclosure of expenses by nature (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfExpensesByNatureExplanatoryDetails |
| 683 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 684 |
Components of general and administrative [Axis] |
Axis |
|
|
tril:ComponentsOfGeneralAndAdministrativeAxis |
| 685 |
Components of general and administrative [Domain] |
Member |
|
|
tril:ComponentsOfGeneralAndAdministrativeDomain |
| 686 |
General and administrative expenses, excluding the below items |
Member |
|
|
tril:GeneralAndAdministrativeExpensesExcludingTheBelowItemsMember |
| 687 |
Salaries, fees and short-term benefits |
Member |
|
|
tril:SalariesFeesAndShorttermBenefitsMember |
| 688 |
Change in fair value of deferred share units |
Member |
|
|
tril:ChangeInFairValueOfDeferredShareUnitsMember |
| 689 |
Share-based compensation |
Member |
|
|
tril:SharebasedCompensationMember |
| 690 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 691 |
Selling, general and administrative expense |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:SellingGeneralAndAdministrativeExpense |
| 692 |
058 - Disclosure - Disclosure of information about key management personnel (Details) |
Network |
* |
* |
http://trilliumtherapeutics.com/role/DisclosureDisclosureOfInformationAboutKeyManagementPersonnelExplanatoryDetails |
| 693 |
Statements [Table] |
Table |
* |
* |
tril:StatementsTable |
| 694 |
Legal Entity [Axis] |
Axis |
|
|
dei:LegalEntityAxis |
| 695 |
Entity [Domain] |
Member |
|
|
dei:EntityDomain |
| 696 |
Statements [Line Items] |
LineItems |
|
|
tril:StatementsLineItems |
| 697 |
Salaries, fees and short-term benefits |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits |
| 698 |
Share-based compensation |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment |
| 699 |
Total |
Concept (Monetary) |
For Period |
Debit |
ifrs-full:KeyManagementPersonnelCompensation |